| A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells P Johnsson, A Ackley, L Vidarsdottir, WO Lui, M Corcoran, D Grandér, ... Nature structural & molecular biology 20 (4), 440-446, 2013 | 493 | 2013 |
| Prostate cancer progression and survival in BRCA2 mutation carriers L Tryggvadóttir, L Vidarsdóttir, T Thorgeirsson, JG Jonasson, ... Journal of the National Cancer Institute 99 (12), 929-935, 2007 | 270 | 2007 |
| Polo-like kinases and acute leukemia O Goroshchuk, I Kolosenko, L Vidarsdottir, A Azimi, C Palm-Apergi Oncogene 38 (1), 1-16, 2019 | 65 | 2019 |
| Breast cancer risk associated with AURKA 91T→ A polymorphism in relation to BRCA mutations L Vidarsdottir, SK Bodvarsdottir, H Hilmarsdottir, L Tryggvadottir, ... Cancer letters 250 (2), 206-212, 2007 | 42 | 2007 |
| The molecular dynamics of long noncoding RNA control of transcription in PTEN and its pseudogene N Lister, G Shevchenko, JL Walshe, J Groen, P Johnsson, L Vidarsdóttir, ... Proceedings of the National Academy of Sciences 114 (37), 9942-9947, 2017 | 37 | 2017 |
| Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition L Vidarsdottir, G Steingrimsdottir, SK Bodvarsdottir, HM Ogmundsdottir, ... Investigational new drugs 30, 425-434, 2012 | 15 | 2012 |
| Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients O Goroshchuk, L Vidarsdottir, AC Björklund, AS Hamil, I Kolosenko, ... Scientific Reports 10 (1), 2688, 2020 | 11 | 2020 |
| Thermal proteome profiling identifies PIP4K2A and ZADH2 as off‐targets of Polo‐like kinase 1 inhibitor volasertib O Goroshchuk, I Kolosenko, E Kunold, L Vidarsdottir, M Pirmoradian, ... The FASEB Journal 35 (7), e21741, 2021 | 10 | 2021 |
| RNAi prodrugs decrease elevated mRNA levels of Polo‐like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients I Kolosenko, O Goroshchuk, L Vidarsdottir, AC Björklund, SF Dowdy, ... The FASEB Journal 35 (5), e21476, 2021 | 9 | 2021 |
| PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma L Vidarsdottir, A Azimi, I Das, I Sigvaldadottir, A Suryo Rahmanto, A Petri, ... Scientific Reports 11 (1), 11023, 2021 | 7 | 2021 |
| Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib L Vidarsdottir, RV Fernandes, V Zachariadis, I Das, E Edsbäcker, ... Melanoma Research 30 (5), 443-454, 2020 | 5 | 2020 |
| Targeting aurora kinases in BRCA2-mutated breast cell lines L Vidarsdottir, S Bodvarsdottir, H Ogmundsdottir, J Eyfjord Cancer Research 68 (9_Supplement), 2395-2395, 2008 | 3 | 2008 |
| AURKA and Breast Cancer in BRCA1/2 Mutation Carriers SK Bodvarsdottir, L Vidarsdottir, JE Eyfjord Cancer Epidemiology Biomarkers & Prevention 16 (11), 2517-2517, 2007 | 3 | 2007 |
| Designing siRNA and evaluating its effect on RNA targets using qPCR and western blot L Vidarsdottir, O Goroshchuk, I Kolosenko, C Palm-Apergi Oligonucleotide-Based Therapies: Methods and Protocols, 53-72, 2019 | 2 | 2019 |
| Functional analysis of long non-coding RNAs in cancer L Vidarsdottir Inst för onkologi-patologi/Dept of Oncology-Pathology, 2017 | 1 | 2017 |
| MicroRNA-190b Targets RFWD3 in Estrogen Receptor–Positive Breast Cancer EA Frick, K Kristjansdottir, S Ragnarsdottir, AI Vilhjalmsson, MR Bustos, ... Breast Cancer: Basic and Clinical Research 18, 11782234241234771, 2024 | | 2024 |
| Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients L Vidarsdottir, EJ Olafsdottir, RB Barkardottir, O Bjarnadottir, JG Jonasson, ... NPJ Breast Cancer 9 (1), 95, 2023 | | 2023 |
| ALL-166: Novel RNAi Prodrugs Targeting Plk1 Induce Specific mRNA Cleavage in Pediatric Acute B-Cell Lymphoblastic Leukemia O Goroshchuk, L Vidarsdottir, AC Björklund, A Hamil, I Kolosenko, ... Clinical Lymphoma Myeloma and Leukemia 20, S163, 2020 | | 2020 |
| PTENpg1 antisense RNA mediates PTEN suppression in vemurafenib resistance and predicts clinical outcome in melanoma patients L Vidarsdottir, A Azimi, J Serviss, C Ingvar, G Jonsson, H Olsson, MF Stolt, ... CANCER RESEARCH 76, 2016 | | 2016 |
| Abstract B28: PTENpg1 antisense RNA mediates PTEN suppression in vemurafenib resistance and predicts clinical outcome in melanoma patients L Vidarsdottir, A Azimi, J Serviss, C Ingvar, G Jönsson, H Olsson, MF Stolt, ... Cancer Research 76 (6_Supplement), B28-B28, 2016 | | 2016 |
